Helsinn Healthcare
Helsinn Healthcare, a Swiss-based pharmaceutical company, has established itself as a leader in the oncology and supportive care sectors since its founding in 1977. Headquartered in Lugano, Switzerland, Helsinn operates globally, with significant presence in Europe, North America, and Asia. The company is renowned for its innovative approach to developing high-quality products that enhance the quality of life for cancer patients, including its flagship anti-emetic treatments. With a strong commitment to research and development, Helsinn has achieved notable milestones, including strategic partnerships and a robust pipeline of therapies. Its dedication to patient-centric solutions and a focus on unmet medical needs have positioned Helsinn as a trusted name in the healthcare industry, recognised for its contributions to cancer care and supportive therapies.
DitchCarbon Score
How does Helsinn Healthcare's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Helsinn Healthcare's score of 18 is lower than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Helsinn Healthcare's reported carbon emissions
In 2023, Helsinn Healthcare reported an emissions intensity of approximately 17,700 kg CO2e per employee. This figure reflects their commitment to monitoring and managing their carbon footprint, although specific total emissions data for the year is not disclosed. In 2022, the emissions intensity was about 16,300 kg CO2e per employee, indicating a slight increase year-on-year. For 2021, Helsinn Healthcare disclosed total emissions of approximately 3,370,000 kg CO2e, broken down into Scope 1 emissions of about 1,175,000 kg CO2e, Scope 2 emissions of approximately 340,000 kg CO2e, and Scope 3 emissions of around 1,855,000 kg CO2e. This comprehensive reporting demonstrates their awareness of emissions across all scopes, including significant contributions from business travel and employee commuting. Despite the detailed emissions reporting for 2021, Helsinn Healthcare has not set specific reduction targets or initiatives, as indicated by the absence of SBTi (Science Based Targets initiative) reduction targets or documented climate pledges. The company appears to be in the early stages of formalising its climate commitments, focusing on emissions tracking rather than established reduction goals. Overall, Helsinn Healthcare's emissions data and climate commitments reflect a growing awareness of sustainability issues, with a need for more structured reduction strategies to align with industry standards.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2012 | 2013 | 2014 | 2015 | 2016 | 2021 | |
|---|---|---|---|---|---|---|
| Scope 1 | 2,955,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | - | - | - | 0,000,000 | 0,000,000 | 000,000 |
| Scope 3 | - | - | - | 0,000,000 | 0,000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Helsinn Healthcare is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
